Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunotherapy
• Clinical Trials

Background:

• Durvalumab is a monoclonal antibody targeting PD-L1.
• It is the first immunotherapy approved for limited-stage small cell lung cancer (LS-SCLC).
• Approvals vary regarding concurrent chemoradiotherapy (cCRT) requirements.

Purpose of the Study:

• To evaluate the efficacy and safety of consolidation durvalumab in LS-SCLC patients.
• To establish durvalumab as a potential new standard of care.

Main Methods:

• Phase III ADRIATIC trial.
• Consolidation intravenous durvalumab (4-weekly for up to 24 months) vs. placebo.
• Patients with LS-SCLC whose disease had not progressed following cCRT.

Main Results:

• Durvalumab significantly improved overall survival and progression-free survival compared to placebo.
• Benefits were observed irrespective of prior cCRT components or prophylactic cranial irradiation.
• Durvalumab demonstrated a manageable tolerability and safety profile.

Conclusions:

• Consolidation durvalumab represents a new standard of care for LS-SCLC patients post-cCRT.
• The ADRIATIC trial provides strong evidence supporting its use.
• Durvalumab offers significant survival benefits in this patient population.